Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder

Urologia Internationalis

Volumn 76, Issue 1, 2006, Pages 51-56

  Gurocak, Serhat ^a,b   Sozen, Sinan ^a   Erdem, Ozlem ^a   Özkan, Seçil ^a   Kordan, Yakup ^a   Alkibay, Turgut ^a   Akyol, Gulen ^a   Bozkirli, Ibrahim ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Bladder cancer; Cyclooxygenase 2; Prognosis; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 30644465313     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089735     Document Type: Article

References (25)

1. Greenlee RT, Murray T, Bolden S, Wings PA: Cancer statistics. Cancer J Clin 2000;50:7-11.
2. 2 pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol 2003;44:435-441.
3. Klein EA, Rogatko A, Herr HW: Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 1992;147:601-605.
4. May M, Helke C, Nitzke T, Vogler H, Hoschke B. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int 2004;72:103-111.
5. Giardiello FM, Offerahus GJA, DuBois RN: The role of non-steroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31:1071-1076.
6. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
7. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Over-expression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
8. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R: Deficiency of either cyclooxygenase (Cox)-1 or Cox-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-3401.
9. Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T: Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 2002;168:2650-2654.
10. Subbaramaiah K, Dannenberg AJ: Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
11. Kim SI, Kwon SM, Kim YS, Hong SJ: Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002;60:816-821.
12. Kubba AK: Non-steroidal anti-inflammatory drugs and colorectal cancer: is there a way forward? Eur Urol 1999;35:892-901.
13. Gridley G, McLaughin JK, Ekborn A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311.
14. Barnes CJ, Cameron IL, Hardman WE, Lee M: Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 1998;77:573-580.
15. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M: Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-455.
16. Hwang D, Scollard D, Byrne J, Leivne E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460.
17. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M: Expression of cyclooxygenase-2 in hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696.
18. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T: Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998:58:3761-3764.
19. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000:89:589-596.
20. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-8.
21. Sheehan KM, Sheehan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254-1257.
22. Pruthi RS, Derksen E, Gaston K: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review J Urol 2003;169:2352-2359.
23. Lui XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825.
24. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
25. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.